Are the benefits of aspirin likely to exceed the risk of major bleeds among people in whom aspirin is recommended for the primary prevention of cardiovascular disease?

CONCLUSION: The benefits of aspirin are likely to exceed the risk of major bleeds among people in whom aspirin is recommended for the primary prevention of CVD. A more cautious approach to the use of aspirin is appropriate for people aged 60-69 years who are likely to have a smaller net benefit from aspirin, particularly those in whom lipid- and blood pressure-lowering therapy has not already been optimised or who have other bleeding risk factors, such as diabetes or smoking. More specific recommendations will be possible when bleeding risk equations are developed to complement the recently developed New Zealand CVD risk equations. PMID: 30359352 [PubMed - in process]
Source: New Zealand Medical Journal - Category: General Medicine Tags: N Z Med J Source Type: research